CTOs on the Move

Dicerna

www.dicerna.com

 
Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body`s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.dicerna.com
  • 33 Hayden Avenue
    Lexington, MA USA 02421
  • Phone: 617.621.8097

Executives

Name Title Contact Details

Funding

Dicerna raised $70M on 03/30/2017
Dicerna raised $100M on 10/29/2018

Similar Companies

Zitomer Pharmacy Inc

Zitomer Pharmacy Inc is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VistaPharm

VistaPharm is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Civica Rx

Civica Rx was created in late 2018 to secure the supply of important medicines hospitals use every day. As of Q2 2023, we have provided over 125 million units of essential medicines to hospitals, enough to help treat over 50 million patients. Recently, we announced we will manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin. Insulin is an exciting project as we are partnering with nearly every corner of the diabetes ecosystem to bring low-cost insulin to people living with diabetes at no more than $30 a vial and no more than $55 for a pack of five pre-filled pens, regardless of insurance status.

Circassia

Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies.

Cingulate

The Investor Relations website contains information about Cingulate Incs business for stockholders, potential investors, and financial analysts.